TRW & Co · Trade, Regulation & ESG
Medical Device Compliance in Singapore
Medical device registration in Singapore is run by the Health Sciences Authority and turns on three choices: the risk class, the evaluation route and who holds the registration. Get them right and some devices reach the market on submission; get them wrong and launches slip by months. This guide covers registration, dealer licensing and post-market duties for 2026.
Key pointOverseas approvals from HSA's five reference regulators decide the evaluation route, and the route decides the timeline: a Class B device with the right approvals can be listed on submission, while a novel Class D device faces a 310-working-day target.
At a glance
Four risk classes
Class A devices are exempt from registration but need a product notification; Classes B, C and D must be registered with HSA before supply.
Reference approvals matter
Approvals from TGA, Health Canada, MHLW, the US FDA or an EU Notified Body unlock the abridged, expedited and immediate routes.
Targets from immediate to 310 days
HSA targets range from immediate listing for qualifying Class B devices to 310 working days for a full-route Class D device.
SHARE replaced MEDICS
Since 14 July 2025, device registrations, Class A notifications and dealer licences are filed in HSA's SHARE portal using Corppass.
Tight vigilance deadlines
Adverse events must be reported within 48 hours for serious public health threats and 10 calendar days for deaths or serious deterioration.
Swipe or scroll →
What medical device registration in Singapore covers
Medical device registration in Singapore is the gateway every manufacturer, importer and distributor has to pass before a device can be supplied to hospitals, clinics, pharmacies or patients. The Health Sciences Authority (HSA) decides whether a product is a medical device, what risk class it falls into and which evaluation route applies, and it lists approved devices on the Singapore Medical Device Register.
Registration is only one of three regulatory layers. The company dealing in the device needs the right dealer's licence, and once the product is on the market a separate set of post-market duties begins: adverse event reporting, field safety corrective actions, change notifications and advertising controls. Commercial plans that ignore any of these layers tend to stall at the point of first shipment.
The legal question usually arrives earlier than teams expect. Is a wellness wearable a medical device? Who should hold the registration if a foreign manufacturer wants to switch distributors later? Can an app go to market on the day it is submitted? These choices shape distribution contracts, timelines and valuation, so they belong at the start of market-entry planning, not at the end.
The legal and regulatory framework
Medical devices are regulated under the Health Products Act 2007 and the Health Products (Medical Devices) Regulations 2010. HSA administers both. A medical device is a health product that acts by physical or mechanical means to diagnose, alleviate, treat, or measure and monitor bodily functions. Products for general well-being that make no specific medical claim, such as massagers or body-toning equipment, fall outside the definition.
HSA's regulatory overview sets out the three obligations that run in parallel: product registration (subject to the Class A exemption), a dealer's licence for anyone who manufactures, imports or supplies devices, and continuing post-market duties. HSA also publishes self-help tools for checking whether a product is a medical device and for working out its risk classification.
Risk classes A to D
Devices are grouped into four risk classes, from Class A (lowest) to Class D (highest). Class A devices are exempt from product registration, but the manufacturer or importer must still submit a product notification. Class B, C and D devices must be registered before supply. The class drives the evaluation route, the documents HSA expects, the fees and the turnaround time.
The SHARE portal
Since 14 July 2025, applications have been made through SHARE (Singapore Health Product Access and Regulatory E-System), which replaced the older MEDICS system. SHARE handles Class B to D registration, Class A notifications, dealer's licences, change of registrant, special access routes and export certificates, and it requires Corppass access. Companies that last filed on MEDICS should check that user roles and authorisations were set up correctly in the new system.
Choosing the evaluation route for medical device registration in Singapore
The single most valuable decision in medical device registration in Singapore is the evaluation route. It depends on three facts: the risk class, how many approvals the device already holds from HSA's overseas reference regulators, and its safe marketing history. HSA's reference regulators are Australia's TGA, Health Canada, Japan's MHLW, the US FDA (510(k), De Novo or PMA) and EU Notified Bodies under the MDR, IVDR and earlier directives. Clearance as a Class I or Class II exempt device by those agencies does not count.
| Class | Route and main condition | Target TAT |
|---|---|---|
| B | Immediate: one reference approval plus three years' marketing, or two approvals; no safety issues | On submission |
| B | Abridged (one reference approval) / Full (none) | 100 / 160 |
| C | Expedited (ECR-1 or ECR-2) / Abridged / Full | 120 / 160 / 220 |
| D | Expedited (EDR: two approvals) / Abridged / Full | 180 / 220 / 310 |
| B, C, D | Full route under the Priority Review Scheme | 104 / 143 / 202 |
| B, C | Immediate route for standalone medical mobile apps (one approval, no safety issues) | On submission |
The figures come from HSA's fees and turnaround time page and its registration overview. They are targets, not guarantees, and the clock stops whenever HSA issues an input request and waits for an answer.
Devices that cannot use the faster routes
Some devices are confined to the full or abridged routes. For Class C, non-bioactive hip, knee and shoulder replacement implants cannot use the expedited route. For Class D, the exclusions include active implantables such as pacemakers, implants in contact with the central circulatory or nervous system, bioactive joint implants, devices with a registrable drug in a secondary role, and HIV and donor-compatibility IVD assays. Any prior rejection or withdrawal by a reference agency also closes the expedited and immediate routes.
The Priority Review Scheme
For devices with no reference approval, the Priority Review Scheme shortens the full route. Route 1 covers devices in oncology, diabetes, ophthalmic, cardiovascular, infectious or skin diseases that address an unmet clinical need. Route 2 covers devices that do not meet both Route 1 criteria. HSA can test whether a device genuinely qualifies, so the justification needs to be documented, not asserted.
Registrants, dealer's licences and the distribution model
The registrant is the Singapore company that holds the registration and answers to HSA for it. Foreign manufacturers usually appoint a local distributor or a regulatory service provider to act as registrant, or set up their own subsidiary. That choice has lasting commercial effects, because the registrant controls the listing and a change of registrant is a separate HSA application with a 40-working-day target.
Distributor as registrant
Fastest and cheapest entry, but it gives the distributor leverage. The agreement must oblige the distributor to cooperate with a transfer on termination and to share technical files only as needed.
Independent registrant
A neutral regulatory service company holds the registration, leaving the manufacturer free to appoint or change distributors. It adds a fee layer and needs clear service-level terms for vigilance work.
Own subsidiary
Maximum control and a platform for regional expansion. It requires incorporation, a dealer's licence, a quality system and people who can run vigilance and complaints locally.
Importer's licence
Needed to bring a device into Singapore. Importers who also sell on to other businesses need a wholesaler's licence as well, unless the supply is only to end users.
Wholesaler's licence
Covers wholesale supply, supply for re-supply, export and commercial samples. HSA does not require it for retail supply to end users, such as a store selling to consumers.
Manufacturer's licence
Covers making, processing, packaging and labelling devices before supply. A licensed manufacturer does not need a separate wholesaler's licence for devices it makes under that licence.
Dealer's licence applicants must show a quality management system. HSA accepts MDSAP, ISO 13485 or GDPMDS certification with audit reports for importers and wholesalers, and MDSAP or ISO 13485 for manufacturers, with ISO 13485 and GDPMDS certificates issued by an SAC-accredited body. Companies dealing only in Class A devices may submit a declaration of conformity instead. New licences and annual renewals have a 10-working-day target.
The distribution contract should mirror these regulatory roles. Our distribution and agency agreements team drafts the regulatory cooperation, vigilance and transfer clauses that keep a manufacturer in control of its listing.
Step-by-step process and timeline
A well-run submission is mostly preparation. HSA expects dossiers in the ASEAN Common Submission Dossier Template (CSDT) format, in English, and it will raise input requests for anything missing.
- Confirm the product is a device. Test intended use and claims against the definition, using HSA's self-help tool. Wellness positioning only works if the labelling, website and sales materials make no medical claims.
- Fix the risk class. Apply the classification rules to the device and every accessory or software module. Classification drives every later step, so record the reasoning.
- Map reference approvals and history. List approvals from TGA, Health Canada, MHLW, FDA and EU Notified Bodies, the dates of marketing and any safety actions, rejections or withdrawals.
- Appoint the registrant and licence the dealer. Decide who holds the registration, put the agreements in place and obtain the importer's, wholesaler's or manufacturer's licence.
- Build the CSDT dossier. Assemble the essential principles checklist, declaration of conformity, design verification and validation, clinical evaluation report, labels, risk analysis and QMS evidence.
- Submit through SHARE and manage input requests. Respond fully and quickly; stop-clock time is the applicant's time, not HSA's.
- Prepare for launch. Clear advertising materials, set up complaint handling and adverse event reporting, and put annual retention fees and licence renewals in the compliance calendar.
For a Class B device with two reference approvals, market access can be immediate. A novel Class D implant with no reference approval should be planned around the 310-working-day full-route target plus stop-clock time.
Documents and evidence to assemble
For a full-route Class B submission, HSA's guide lists an executive summary, the essential principles checklist, a declaration of conformity, the device description, design verification and validation documents (preclinical studies, sterilisation validation, shelf-life studies), the clinical evaluation report with supporting studies, labels, a risk analysis, manufacturing and sterilisation sites, a manufacturing flowchart and proof of a quality system such as ISO 13485 or MDSAP. A letter of authorisation and a list of configurations are also required.
- Reference approval certificates, with dates and the exact model scope they cover.
- A marketing history statement and a summary of global complaints, recalls and safety actions.
- Labelling and instructions for use that match the approved intended use word for word.
- For software, cybersecurity, data integrity and lifecycle documentation under HSA's software guidance.
- The registrant authorisation and the distribution or regulatory services agreement.
Inconsistencies between the dossier, the label and the marketing claims are the most common trigger for input requests and later enforcement.
Post-market duties after medical device registration in Singapore
Registration is not the finish line. Product registrants, manufacturers, importers and suppliers must each report adverse events to HSA. The clock starts when anyone in the company, including a sales representative, becomes aware of the event.
- Serious threat to public health: within 48 hours.
- Death or serious deterioration in health: within 10 calendar days.
- Events that could cause death or serious injury if they recurred: within 30 calendar days.
- A final investigation report is due within 30 days of the initial report.
Where more than one dealer is involved, each must report. Field safety corrective actions, from recalls to software updates and relabelling, are reported through HSA's OSCAR system and usually involve notices to users and healthcare professionals. Our guide to product recalls in Singapore healthcare covers that process in more detail.
Change notifications
Most changes to a registered device need HSA approval before they are implemented. Target times range from 30 working days for administrative changes to 75 (Class C) or 90 (Class D) for technical changes. A change in intended use or risk class cannot be handled by change notification at all; it needs a new registration.
The registration is the asset. Whoever holds it controls how quickly the device can change distributors, update its labelling or respond to a safety signal.
Advertising and promotion
Advertisements do not need prior HSA approval, but the advertiser is responsible for compliance with the Health Products Act and HSA's GN-08 guidance. Professional-use-only devices cannot be advertised to the public, and devices cannot be promoted to the public with claims to prevent, alleviate or cure listed conditions such as cancer, diabetes or hypertension. The Singapore Code of Advertising Practice also applies. See our note on healthcare advertising controls.
Software, apps and AI-enabled devices
Software that has a medical purpose, such as diagnosis, monitoring or treatment, is a medical device. HSA's digital health guidance includes the Regulatory Guidelines for Software Medical Devices (April 2020), which cover cybersecurity, data integrity and lifecycle management, and the AI in Healthcare Guidelines (AIHGle 2.0) issued jointly with MOH, which allocate responsibilities between developers, deploying healthcare organisations and professional users.
Standalone medical apps with one reference approval and no safety issues can use the immediate route, with HSA reviewing qualification in the background. Frequent software releases create a change-control question: which updates are significant enough to need a change notification? Build that triage into the release process. Where the device processes patient data, our health data governance and telemedicine and digital health teams address the PDPA and service-licensing overlay.
Risks and common mistakes
Letting the distributor hold the registration without exit terms
Many manufacturers let their first distributor register the device because it is quick. The problem appears when the relationship ends. HSA treats a change of registrant as a separate application, and the outgoing registrant's cooperation makes it much smoother. If the distribution agreement is silent, the distributor can slow the transfer while it negotiates compensation. The agreement should require the distributor to consent to a change of registrant, hand over vigilance records and complaint files, and stop holding itself out as the registrant on termination. It should also restrict the distributor's use of the technical file to regulatory purposes.
Misreading the reference approval
Expedited and immediate routes depend on the exact approval held. A US 510(k) counts; a Class I or Class II exempt status does not. EU certificates count only if issued by a Notified Body under the listed instruments, and the scope must cover the models being registered. Companies sometimes rely on an approval that covers a predecessor model or a different configuration, then face an input request or a downgrade to the full route. Map every model and accessory against the certificate before choosing the route, and disclose any prior rejection or withdrawal, which rules out the faster routes.
Wellness claims that turn a product into a device
A product marketed for general well-being is outside the device regime, but a single claim to detect, monitor or treat a condition can bring it inside. The test looks at the intended purpose shown by labels, instructions, websites, app-store text and sales scripts, not just the box. Consumer technology businesses often launch as wellness products and then add health features or partner with clinics. Each change should be screened against the definition before release. Supplying an unregistered device is an offence, and retrofitting compliance after a launch is costly.
Treating vigilance as the manufacturer's job
HSA expects each dealer involved in a reportable event to submit its own report, and the timeline starts when anyone in the company hears of it. A distributor that forwards complaints to the overseas manufacturer and waits for instructions can miss the 48-hour or 10-day window. Local registrants and dealers need a written procedure, trained staff, an out-of-hours contact and agreements that require the manufacturer to share investigation results quickly. Missed reports are a common finding in inspections and can damage the relationship with HSA.
Implementing changes before approval
Label updates, new manufacturing sites and software releases are routine for the manufacturer, but in Singapore many require HSA approval before implementation. Shipping the changed device first and notifying later leaves the product out of line with its registration. Build a regulatory change gate into the manufacturer's change control system, so that Singapore impacts are assessed alongside the EU and US. Group identical changes into one notification where HSA's grouping rules allow, to save fees and time.
Cross-border angle: using Singapore as a regional base
Singapore is often the first ASEAN market for a device because of HSA's reliance on reference regulators and its predictable timelines. Many companies then use the Singapore registration and CSDT dossier as the basis for submissions in other ASEAN markets that also use the ASEAN dossier format, while recognising that each country makes its own decision.
For manufacturers in Bangladesh, China or the UAE entering Singapore, the immediate hurdle is often the lack of a reference approval, which pushes the device onto the full route. Planning an FDA or EU approval first can shorten the Singapore timeline overall. For UK manufacturers, note that a UKCA mark is not one of HSA's listed reference approvals, whereas an EU Notified Body certificate is. Where a group runs regional distribution from Singapore, customs and trade compliance and transfer pricing need to fit the licensing structure.
Before choosing a Singapore distributor, decide where the registration will sit in five years' time. Restructuring a registration is slower than restructuring a contract, and the answer affects how much leverage the distributor has from day one.
How TRW & Co helps with medical device registration in Singapore
We advise manufacturers, distributors and investors on the legal side of medical device registration in Singapore and the contracts around it. We work alongside regulatory affairs consultants who prepare technical dossiers, and where Singapore court or tribunal representation is required, we work alongside Singapore-qualified counsel.
Route and classification analysis
We review intended use, claims and reference approvals, and set out the available evaluation routes with their timelines and conditions, so that launch plans rest on a defensible position.
Registrant and distribution structuring
We compare distributor, independent registrant and subsidiary models and draft the agreements, including transfer-on-termination, vigilance and technical file controls.
Post-market compliance
We prepare adverse event, FSCA and change-control procedures that allocate duties between manufacturer and local dealers, and review advertising before launch.
Transactions and disputes
We run regulatory due diligence on device businesses and, with our healthcare regulation and disputes teams, handle registrant transfers and distributor exits.
See our practices for the wider healthcare and life sciences offering, or contact us to discuss a device. Our guide to medical device compliance in practice adds further detail.
Checklist for decision-makers
- Have we confirmed that the product is a medical device, and recorded its risk class with reasons?
- Which reference approvals do we hold, for exactly which models, and do they unlock the abridged, expedited or immediate route?
- Who will be the registrant, and can we move the registration if the distributor relationship ends?
- Does every dealer in the chain hold the right licence and quality system certificate?
- Is the CSDT dossier consistent with the label, instructions and marketing claims?
- Do we have an adverse event procedure that meets the 48-hour, 10-day and 30-day deadlines?
- Is there a change-control gate for Singapore before labelling, site or software changes go live?
- Are retention fees, licence renewals and reporting deadlines in a calendar with a named owner?
Teams that can answer each question clearly are well placed to make medical device registration in Singapore a predictable step rather than a source of delay.
Frequently asked questions
01Does a Class A medical device need to be registered in Singapore?
No. Class A devices are exempt from product registration with HSA. However, the manufacturer or importer must still submit a Class A product notification through SHARE, and the companies dealing in the device still need the appropriate dealer's licence. For Class A-only businesses, HSA accepts a declaration of conformity to a quality management system in place of a certificate and audit report. Post-market duties, including adverse event reporting and field safety corrective actions, continue to apply. Confirm the class carefully, because an error that should have placed the device in Class B means it was supplied without registration.
02Can a foreign manufacturer register a device directly with HSA?
In practice the registration is held by a Singapore entity that answers to HSA, so a foreign manufacturer works through a local registrant: its distributor, an independent regulatory service company or its own Singapore subsidiary. Each option has trade-offs in cost, control and speed. The most important protection is contractual: the agreement with the registrant should require cooperation with a change of registrant, which HSA handles as a separate application with a 40-working-day target, and should limit use of the technical file to regulatory purposes.
03How long does medical device registration in Singapore take?
It depends on class and route. HSA's targets, in working days and excluding stop-clock time, are 100 (abridged) and 160 (full) for Class B; 120, 160 and 220 for Class C expedited, abridged and full; and 180, 220 and 310 for Class D. Qualifying Class B devices and standalone medical apps can be listed immediately on submission. The Priority Review Scheme shortens full-route targets to 104, 143 and 202 working days. Input requests stop the clock, so dossier quality strongly affects the real timeline.
04Is our health app or AI tool a medical device?
It is if it is intended for a medical purpose such as diagnosing, monitoring or treating a condition. HSA assesses intended purpose from the labelling, app-store text, website and other claims. General wellness tools without medical claims fall outside the regime. If the app is a device, HSA's software guidance applies, including cybersecurity and lifecycle requirements, and the immediate route may be available for standalone apps with one reference approval and no safety issues. AI tools should also be assessed against the AIHGle 2.0 guidelines issued by MOH and HSA.
05What must we report to HSA after the device is on the market?
Product registrants, manufacturers, importers and suppliers must report adverse events: within 48 hours for a serious threat to public health, within 10 calendar days for death or serious deterioration in health, and within 30 calendar days for events that could cause death or serious injury if repeated. A final investigation report follows within 30 days of the initial report. Field safety corrective actions such as recalls, software updates and relabelling are reported through HSA's OSCAR system, and most changes to the registered device need approval before implementation.
06Do we need HSA approval for medical device advertisements?
No prior approval is needed, but the advertiser is responsible for complying with the Health Products Act and HSA's GN-08 guidance on advertisements and sales promotion. Professional-use-only devices may only be advertised to qualified practitioners or in professional publications. Devices cannot be promoted to the public with claims to prevent, alleviate or cure listed conditions such as cancer, diabetes and hypertension. Claims must be truthful and substantiated, must not guarantee results or claim complete safety, and must comply with the Singapore Code of Advertising Practice.
07Which dealer's licence does a distributor need?
An importer's licence to bring devices into Singapore, and a wholesaler's licence to supply them to other businesses, export them or supply commercial samples. HSA does not require a wholesaler's licence for supply only to end users, such as retail sales. A manufacturer's licence covers making, processing, packaging and labelling. Importers and wholesalers must show MDSAP, ISO 13485 or GDPMDS certification with an audit report, with ISO 13485 and GDPMDS certificates issued by an SAC-accredited body. HSA's target for new licences and renewals is 10 working days.
Sources and official materials
- Health Products (Medical Devices) Regulations 2010 — Registration, dealer licensing and post-market rules
- HSA: Registration overview of medical devices — Evaluation routes, reference agencies and exclusions
- HSA: Fees and turnaround time for medical devices — Target timelines, change notifications and retention fees
- HSA: Apply for a medical device dealer's licence — Importer, wholesaler and manufacturer licences; QMS evidence
- HSA: Adverse events reporting of medical devices — 48-hour, 10-day and 30-day reporting timelines
- HSA: Digital health — Software medical devices, apps and AI guidance
- HSA: Introducing SHARE — SHARE portal launch on 14 July 2025, replacing MEDICS
General information only, current as at 20 October 2026. It is not legal advice and does not create a lawyer–client relationship. Singapore law and regulatory practice change; check current official sources and take advice on the facts of your matter.